Aytu Biopharma Inc reports results for the quarter ended in September - Earnings Summary

Aytu Biopharma

14/11/2022 22:04

* Aytu Biopharma Inc  AYTU.OQ  reported a quarterly adjusted
loss
of 6 cents​​ per share for the quarter ended in September. The
lone analyst forecast for the quarter was for a loss of 18 cents
per share.
    * Revenue rose 26.3% to $27.66 million from a year ago;
analysts
expected $24.30 million. 
    * Aytu Biopharma Inc's reported EPS for the quarter was a
loss
of 6 cents​.
    * The mean earnings estimate of analysts had risen by
about 25% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Aytu Biopharma Inc shares had risen by 4.6% this
quarter and
lost 85.7% so far this year.
    * The company reported a quarterly loss of $2.88 million.
    * Wall Street's median 12-month price target for Aytu
Biopharma
Inc is $5.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 10:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.18          -0.06          Beat
 Jun. 30 2022      -0.37          -0.49          Missed
 Mar. 31 2022      -0.41          -1.79          Missed
 Dec. 31 2021      -0.58          -0.44          Beat